Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 5, 2010, Pages 886-891

  Yamamoto, Shuji ^a,b   Nakase, Hiroshi ^a   Matsuura, Minoru ^a   Honzawa, Yusuke ^a   Masuda, Satohiro ^c   Inui, Ken Ichi ^c   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Infliximab; Tacrolimus; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; LIVER ENZYME; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; TACROLIMUS; AZATHIOPRINE DERIVATIVE; CORTICOSTEROID; PREDNISONE; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INFUSION REACTION; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SYMPTOM; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; ASSESSMENT OF HUMANS; COLON RESECTION; CORTICOSTEROID THERAPY; CYTAPHERESIS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; ENZYME BLOOD LEVEL; HYPERTRANSAMINASEMIA; INFUSION RELATED REACTION; MIDDLE AGED; MODIFIED TRUELOVE WITTS SEVERITY INDEX; YOUNG ADULT; ADOLESCENT; COLITIS, ULCERATIVE; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; KAPLAN MEIER METHOD; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951725509     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06206.x     Document Type: Article

References (34)

1. Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 2002 347 : 417 429.
2. Sands BE. Inflammatory bowel disease: past, present, and future. J. Gastroenterol. 2007 42 : 16 25.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007 369 : 1641 1157.
4. Faubion WA Jr., Loftus EV Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 : 255 260.
5. Ogata H, Matsui T, Nakamura M et al. A randomized dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis A randomized dose finding study of oral tacrolimus. Gut 2006 55 : 1255 1262.
6. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid- refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 2006 101 : 1048 1056.
7. Fellermann K, Tanko Z, Herrlinger KR et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel. Dis. 2002 8 : 317 324.
8. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm. Bowel. Dis. 2007 13 : 129 134.
9. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J. Pediatr. Gastroenterol. Nutr. 2007 45 : 306 311.
10. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment. Pharmacol. Ther. 2003 18 : 415 423.
11. Yamamoto S, Nakase H, Mikami S et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment. Pharmacol. Ther. 2008 28 : 589 597.
12. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunol. 1993 30 : 1443 1453.
13. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005 353 : 2462 2476. (Pubitemid 41770166)
14. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 2008 6 : 1112 1116.
15. Mañosa M, López San Román A, Garcia-Planella E et al. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009 80 : 30 5.
16. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990 336 : 16 19.
17. Cohen RD, Brodsky AL, Hannauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm. Bowel. Dis. 1999 5 : 1 10.
18. Kohn A, Daperno M, Armuzzi A et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment. Pharmacol. Ther. 2007 26 : 747 756.
19. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel. Dis. 2007 13 : 123 128.
20. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000-2006. Aliment. Pharmacol. Ther. 2007 25 : 1055 1060.
21. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 1811.
22. Venkataramanan R, Swaminathan A, Prasad T et al. Clinical pharmacokinetics of tacrolimus. Clin. Pharmacokinet. 1995 29 : 404 430.
23. Ptachcinski RJ, Venkataramanan R, Burckart GJ et al. Cyclosporine kinetics in healthy volunteers. J. Clin. Pharmacol. 1987 27 : 243 248.
24. Ternant D, Aubourg A, Magdelaine-Beuzelin C et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther. Drug. Monit. 2008 30 : 523 529.
25. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J. Antibiot. (Tokyo) 1987 40 : 1256 1265. (Pubitemid 17138110)
26. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 1994 330 : 1841 1845.
27. Carbonnel F, Boruchowicz A, Duclos B et al. Intravenous cyclosporine in attacks of ulcerative colitis: short term and long term responses. Dig. Dis. Sci. 1996 41 : 2471 2476.
28. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006 4 : 621 630.
29. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009 58 : 501 508.
30. Ferrante M, D'Hoore A, Vermeire S et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm. Bowel. Dis. 2009 15 : 1062 1070.
31. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
32. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004 350 : 876 885.
33. Su C, Salzberg BA, Lewis JD et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am. J. Gastroenterol. 2002 97 : 2577 2584.
34. Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open label multicentre study. Aliment. Pharmacol. Ther. 2003 18 : 175 181.